Pharmacists Navigate an Evolving Immunotherapy Landscape in Advanced Non–Small Cell Lung Cancer

Why It Matters

Pharmacist‑driven workflows accelerate appropriate immunotherapy use, improving outcomes and reducing treatment delays in a rapidly expanding NSCLC market.

Key Takeaways

• Pharmacists drive early biomarker testing for NSCLC patients
• Cemiplimab shows survival benefit as monotherapy and combo
• Pharmacists manage access programs and prior‑authorizations
• Order‑set development standardizes dosing and toxicity checks
• Combination regimens favored for low PD‑L1 or high burden

Pulse Analysis

The rise of immune checkpoint inhibitors has reshaped advanced NSCLC treatment, but the complexity of biomarker‑guided therapy demands specialized coordination. Oncology pharmacists now sit at the nexus of diagnostic testing and therapeutic decision‑making, ensuring PD‑L1 and molecular results are obtained promptly. By leveraging liquid biopsies and streamlining tissue workflows, they mitigate the testing delays that historically postponed immunotherapy initiation, directly influencing time‑to‑treatment metrics that correlate with survival.

Cemiplimab’s recent phase 3 data have positioned it as a versatile option, delivering comparable overall survival to other PD‑1 agents in patients with high PD‑L1 expression and extending benefits when paired with platinum‑based chemotherapy. Pharmacists translate these trial outcomes into formulary decisions, balancing efficacy with safety profiles, dosing schedules, and patient comorbidities. Their expertise in navigating payer requirements—through free‑sample programs, prior‑authorization strategies, and patient‑assistance applications—removes financial barriers, expanding access to high‑value regimens across community and academic settings.

Beyond individual drug management, pharmacists are standardizing care through electronic order‑set creation, embedding toxicity monitoring, dose‑adjustment algorithms, and supportive‑care recommendations. This systematic approach reduces variability, improves adherence to guideline‑based regimens, and supports multidisciplinary teams in delivering consistent, high‑quality oncology care. As the immunotherapy pipeline continues to grow, the pharmacist’s role will become even more pivotal in integrating novel agents, optimizing combination strategies, and sustaining the momentum of improved outcomes for NSCLC patients.